Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Gilead Sciences Inc (GILD) Insider Trading Activity

    Healthcare • Drug Manufacturers - General • 18,000 employees

    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

    Total Value

    -$18,264,675.22

    Total Shares

    1,719,387

    Average Trade Value

    -$280,995.00

    Most Active Insider

    Dickinson Andrew D

    Total Activity: $41,668,175

    Largest Single Transaction

    $11,867,119

    by Dickinson Andrew D on Nov 29, 2024

    30-Day Activity

    31 Transactions

    Volume: 1,745,055 shares
    Value: $11,492,175

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    10% Owner
    Dec 18, 2024 1,759,978 $1,830,377 9,105,451 (+19.3%) Purchase
    Chief Financial Officer
    Officer
    Dec 16, 2024 8,500 $781,660 132,373 (-6.4%) Sale
    Svp, Controllership
    Officer
    Dec 13, 2024 157 $10,000 37,533 (+0.4%) Exercise/Conversion
    Svp, Controllership
    Officer
    Dec 13, 2024 157 $14,421 37,078 (-0.4%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Dec 10, 2024 3,640 $0 142,559 (+2.6%) Exercise/Conversion
    Chairman CEO
    Director, Officer
    Dec 10, 2024 10,295 $0 506,290 (+2.0%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Dec 10, 2024 306 $28,256 21,312 (-1.4%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Dec 10, 2024 901 $0 37,486 (+2.4%) Exercise/Conversion
    Chief Commercial Officer
    Officer
    Dec 10, 2024 1,739 $160,579 75,140 (-2.3%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Dec 10, 2024 408 $37,675 37,078 (-1.1%) Payment of Exercise Price
    Evp, Corporate Affairs Gc
    Officer
    Dec 10, 2024 639 $0 21,618 (+3.0%) Exercise/Conversion
    Chairman CEO
    Director, Officer
    Dec 10, 2024 4,762 $439,723 501,528 (-0.9%) Payment of Exercise Price
    Chief Commercial Officer
    Officer
    Dec 10, 2024 3,752 $0 76,879 (+4.9%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Dec 10, 2024 3,820 $0 84,621 (+4.5%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Dec 10, 2024 1,686 $155,685 140,873 (-1.2%) Payment of Exercise Price
    Chief Medical Officer
    Officer
    Dec 10, 2024 1,771 $163,534 82,850 (-2.1%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Nov 29, 2024 26,170 $1,515,766 183,719 (+14.2%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 65,960 $4,795,292 387,564 (+17.0%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 127,930 $11,867,119 138,919 (-92.1%) Sale
    Chief Financial Officer
    Officer
    Nov 29, 2024 33,660 $2,314,125 217,379 (+15.5%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 120,715 $11,198,151 266,849 (-45.2%) Sale
    Chief Financial Officer
    Officer
    Nov 29, 2024 18,630 $1,374,335 157,549 (+11.8%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 60,885 $4,378,240 278,264 (+21.9%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 43,340 $3,150,818 321,604 (+13.5%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Nov 27, 2024 10,399 $956,708 80,801 (-12.9%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 5,200 $477,381 94,399 (-5.5%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 88,119 $5,761,220 245,012 (+36.0%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Nov 27, 2024 3,199 $293,679 91,200 (-3.5%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 57,294 $3,318,468 156,893 (+36.5%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Nov 27, 2024 88,119 $8,106,948 99,599 (-88.5%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 57,294 $5,259,297 187,718 (-30.5%) Sale
    Director
    Nov 26, 2024 4,121 $252,823 15,708 (+26.2%) Exercise/Conversion
    Director
    Nov 26, 2024 5,879 $359,618 11,587 (+50.7%) Exercise/Conversion
    Director
    Nov 26, 2024 6,788 $620,356 8,920 (-76.1%) Sale
    Chief Medical Officer
    Officer
    Nov 6, 2024 25,000 $1,448,000 125,189 (+20.0%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Nov 6, 2024 5,000 $457,500 99,599 (-5.0%) Sale
    Chief Commercial Officer
    Officer
    Nov 6, 2024 5,000 $456,400 73,127 (-6.8%) Sale
    Chief Medical Officer
    Officer
    Nov 6, 2024 20,590 $1,883,985 104,599 (-19.7%) Sale
    Evp, Corporate Affairs Gc
    Officer
    Oct 25, 2024 242 $21,538 20,979 (-1.2%) Payment of Exercise Price
    Evp, Corporate Affairs Gc
    Officer
    Oct 25, 2024 514 $0 21,221 (+2.4%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Oct 1, 2024 2,000 $167,660 100,189 (-2.0%) Sale
    Chief Commercial Officer
    Officer
    Sep 12, 2024 15,925 $1,341,363 91,559 (-17.4%) Sale
    Chief Commercial Officer
    Officer
    Sep 12, 2024 13,432 $1,118,214 78,127 (-17.2%) Sale
    Chief Medical Officer
    Officer
    Sep 12, 2024 25,000 $1,448,000 123,435 (+20.3%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Sep 12, 2024 21,246 $1,795,287 102,189 (-20.8%) Sale
    Chief Commercial Officer
    Officer
    Sep 10, 2024 1,734 $141,217 107,484 (-1.6%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Sep 10, 2024 901 $0 36,877 (+2.4%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Sep 10, 2024 307 $25,002 20,707 (-1.5%) Payment of Exercise Price
    Chief Medical Officer
    Officer
    Sep 10, 2024 3,821 $0 100,201 (+3.8%) Exercise/Conversion
    Svp, Controllership
    Officer
    Sep 10, 2024 292 $23,780 36,585 (-0.8%) Payment of Exercise Price
    Chairman CEO
    Director, Officer
    Sep 10, 2024 4,749 $386,759 495,995 (-1.0%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Sep 10, 2024 3,641 $0 140,601 (+2.6%) Exercise/Conversion
    Chief Commercial Officer
    Officer
    Sep 10, 2024 3,752 $0 109,218 (+3.4%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Sep 10, 2024 1,682 $136,982 138,919 (-1.2%) Payment of Exercise Price
    Evp, Corporate Affairs Gc
    Officer
    Sep 10, 2024 639 $0 21,014 (+3.0%) Exercise/Conversion
    Chairman CEO
    Director, Officer
    Sep 10, 2024 10,295 $10,000 500,744 (+2.1%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Sep 10, 2024 1,766 $143,823 98,435 (-1.8%) Payment of Exercise Price
    Chief Commercial Officer
    Officer
    Aug 28, 2024 9,513 $742,299 105,466 (-9.0%) Sale
    Chief Commercial Officer
    Officer
    Aug 13, 2024 5,490 $406,150 114,979 (-4.8%) Sale
    Svp, Controllership
    Officer
    Aug 10, 2024 980 $72,187 35,976 (-2.7%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Aug 10, 2024 3,678 $10,000 36,956 (+10.0%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Jul 25, 2024 514 $0 12,145 (+4.2%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Jul 25, 2024 2,917 $223,180 11,631 (-25.1%) Payment of Exercise Price
    Evp, Corporate Affairs Gc
    Officer
    Jul 25, 2024 8,230 $0 20,375 (+40.4%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Jul 1, 2024 2,000 $137,260 96,380 (-2.1%) Sale